



Treatment Information

Treatment typically begins with an individual assessment of the patient's functional limitations and a plan of care is then designed to help them reach their goals. A treatment program typically consists of 10–24 therapy sessions, and may include some of the following:

- Anodyne® Therapy 30 minutes 3x per week
- Stretching and strengthening exercises
- Dynamic and static balance exercises
- Massage and other therapeutic modalities for pain

Prescribing Information

Anodyne® Therapy is indicated by the US FDA to temporarily increase circulation and reduce pain, stiffness and muscle spasm. It has been used safely for over 12 years on hundreds of thousands of patients. Anodyne® Therapy should not be used directly over an active malignancy or over the womb of a pregnant woman. With increased activities during therapy, patients should always monitor their blood sugars carefully. There are no known drug interactions or side effects, other than a slight risk of a superficial burn if therapy protocols and precautions are not followed. For a listing of your local Anodyne® Therapy Providers, please visit <http://www.anodynetherapy.com/CareCenters>.

Will your patients require ongoing treatment?

Patients with an acute injury or problem, more than likely, will not require ongoing treatments. Since there is no known cure for the conditions that contribute to chronic extremity pain or circulatory impairment, these patients **will** require ongoing treatments. The comprehensive care provided by Anodyne® Therapy Providers gives each patient a jump start towards improving their condition. There are two systems available for patient home use, the Freedom 300 and the Model 120. With affordable financing options offered for both systems, most everyone can afford to continue their treatments at home.



Patients typically feel a soothing warmth as circulation increases.

ISO 13485 Quality Registration, CE Mark
UL/CSA Approved Medical Device



Anodyne® Therapy Professional
480 System



Anodyne Therapy, LLC
13570 Wright Circle
Tampa, FL 33626 USA

800.521.6664 or +1 813.342.4432
FAX 800.496.8323 or +1 813.342.4417
CUSTOMER CARE FAX 800.835.4581 or +1 813.342.4418
EMAIL contact@anodynetherapy.com

www.anodynetherapy.com

Your Local Anodyne® Therapy Provider



Better Care. Better Services. Better Results.
Dr. Malak Azab, PT, DPT, TPI CGFI, CKTP
Doctor of Physical Therapy

Conveniently Located:

2539 Middle Country Rd., Suite 101
Centereach, NY 11720
631-467-3381
Fax: 631-467-3383

681 Whiskey Road
Ridge, NY 11961
631-744-8014
Fax: 631-744-8018

www.StTereizaPT.com

1. Burke. "Infrared photo energy may reduce neuropathic pain." *Practical Pain Management* 7.6 (2007): 57-63. Print.
2. Cohen. "The role of nitric oxide and other endothelial-derived vasoactive substances in vascular disease." *Progress In Cardiovascular Disease* 38.2 (1995): 105-28. Pub Med. Web. 5 Nov. 2009. <<http://www.ncbi.nlm.nih.gov/pubmed/7568902>>.
3. Ferreira, Duarte, Lorenzetti. "The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release." *European Journal of Pharmacology* 201 (1991): 121-22. Pub Med. Web. 10 Nov. 2009. <<http://www.ncbi.nlm.nih.gov/pubmed/1665419>>.
4. Harkless, DeLellis, Carnagie, and Burke. "Improved foot sensitivity and pain reduction in patients with peripheral neuropathy after treatment with MIRE." *Journal of Diabetes and Its Complications* 20.2 (2009): 81-87. Print.
5. Lohr et al. "Enhancement of nitric oxide release from nitrosyl hemoglobin and nitrosyl myoglobin by red/near infrared radiation." *Journal of Molecular Cellular Biology* 26.5 (2009): 433-42. Pub Med. Web. 5 Nov. 2009. <<http://www.ncbi.nlm.nih.gov/pubmed/19328206>>.
6. Moilanen, and Vapaatalo. "Nitric Oxide in Inflammation and Immune Response." *Ann Med* 27.3 (1995): 359-67. Pub Med. Web. 8 Nov. 2009. <<http://www.ncbi.nlm.nih.gov/pubmed/7546626>>.
7. Traud, and Van Bibber. "The Role of Nitric Oxide in Insulin Dependent Diabetes Mellitus - Related Vascular Complications." *The Western Journal of Medicine* 162.5 (1995): 439-45. Print.
8. White, Thornton, Efron, and Barbul. "Enhancement of Fibroblast Synthesis By Nitric Oxide." *Nitric Oxide* 4.6 (2000): 572-82. Pub Med. Web. 5 Nov. 2009. <<http://www.ncbi.nlm.nih.gov/pubmed/11139365>>.
9. Ziche, M., and L. Mordidelli. "Nitric Oxide and Angiogenesis." *Journal of Neuro-Oncology* 50.1-2 (2004): 139-48. SpringerLink. Web. 11 Nov. 2009. <<http://www.springerlink.com/content/q14331n450852365>>.

©2009 Anodyne Therapy, LLC. All rights reserved. Anodyne® Therapy and MIRE® are trademarks of Anodyne Therapy, LLC.
U.S. Patent Numbers: 5,358,503 and 6,607,550 Canadian Patent: 2,181,467 European Patent: 0741594

MR-09200 Rev E – November 2009

Referring Provider



Don't just help your
patients live with pain.
Help them live.



Anodyne® Therapy

Clinically Proven Results



Anodyne® Therapy is medical device that emits infrared light at a wavelength of 890 nm, and can be applied to any area of the body. Anodyne® Therapy is indicated by the US FDA to temporarily increase circulation and reduce pain, stiffness and muscle spasm. There are over 6,000 US Anodyne® Therapy Providers, and by adding Anodyne® Therapy to a plan of care, Healthcare Providers are better able to address the source of many types of acute and chronic pain, instead of just treating the symptoms. The Anodyne® Therapy Systems have been prescribed and used by over 20,000 doctors and therapists - who trust its clinical effectiveness. **Clinical applications include (but are not limited to) treatment of: acute pain/injuries, chronic pain and or poor circulation in the extremities caused by chemotherapy, diabetes, vascular diseases, etc, muscle spasm and muscle stiffness.**




The data is compelling.

In addition to an extensive amount of published evidence on the effects of infrared therapy devices with similar wavelengths (810-940nm), there have been 13 published peer reviewed studies demonstrating positive effects for Anodyne® Therapy Systems specifically!

Our largest study, involving 2239 patients was published in the Journal of Diabetes and Its Complications (2006). This study demonstrated a mean 67% pain reduction after a clinical treatment program involving Anodyne® Therapy.⁴

Another study involving 493 patients, examining changes in pain levels of lower extremity pain (Diabetic and Non-Diabetic), was published in the journal of Practical Pain Management (2007). This study demonstrated a 64% reduction in pain. Furthermore, this study reported that 51% of patients studied were able to reduce their use of pain medications.¹



It's effective for pain relief because

It works through the local release of Nitric Oxide.


Clinical Research has linked Nitric Oxide with:

- Increases in local circulation²
- Reduction of pain³
- Reduction in inflammation⁶
- Angiogenesis⁹
- Collagen synthesis⁸


Researchers have discovered that near infrared light increases the release of nitric oxide (NO) from hemoglobin and myoglobin with resulting positive biocellular response.⁵ Nitric oxide has been studied for many years, however, interest has peaked in the last 10-15 years as a result of the discovery of nitric oxide's role as a signaling mechanism in the human body - with the researchers receiving the The Nobel Prize in Physiology in 1998.

In addition to the regulation of the processes noted above, nitric oxide plays a very important role in the vascular system and is also known as 'the endothelium derived relaxing factor'. When nitric oxide is released it stimulates the endothelial lining of both arterial and venous blood vessels, causing vasodilation.² In addition, as Ferrieira et al. discuss, nitric oxide also plays a direct role in pain relief.³

Nitric oxide is particularly significant for people with diabetes. In their paper 'Nitric Oxide and Diabetic Complications', Traub and Van Bibber note that "nitric oxide metabolism and vascular responsiveness to nitric oxide are altered in diabetics", and conclude that, "patients with diabetes may benefit from therapeutic agents that target nitric oxide pathways."⁷



Perfusion increase after 20 minutes of Anodyne® Therapy



*As measured by Moor Scanning Laser Doppler

